| Old Articles: <Older 4781-4790 Newer> |
|---|
 |
The Motley Fool
April 22, 2008
Brian Lawler |
No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year.   |
The Motley Fool
April 22, 2008
Brian Orelli |
Amylin Treads Water One-drug wonders like Amylin Pharmaceuticals can't get away with stagnant growth. |
The Motley Fool
April 22, 2008
Rich Duprey |
Foolish Forecast: No Sizzle at Candela In advance of earnings, analysts expect sales from aesthetic laser maker Candela to be essentially flat. |
The Motley Fool
April 22, 2008
Brian Lawler |
Lilly in Full Financial Bloom Pharmaceutical Eli Lilly boosts revenue in the first quarter, but its drug-pipeline progress falls short of spectacular. |
The Motley Fool
April 21, 2008
Brian Lawler |
Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits. |
Fast Company
May 2008
Greg Lindsay |
Medical Leave Your next heart surgery could well be in Bangkok -- but don't worry, it'll be "in network." How your health care is taking wing ... |
The Motley Fool
April 18, 2008
Brian Orelli |
Big Deal for Small RNAs Glaxo buys into Regulus' microRNA research. |
The Motley Fool
April 18, 2008
Brian Lawler |
More Good News About Cancer Vaccines Pfizer's deal with Avant for an immunotherapy for brain cancer is promising. |
The Motley Fool
April 18, 2008
Brian Orelli |
Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter. |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
| <Older 4781-4790 Newer> Return to current articles. |
